MHRA
- Local brand name: Neofordex
- Status: approved
🇬🇧 Decadron in United Kingdom
NICE has issued 22 UK HTA decisions
Marketing authorisation
Health technology assessment
22 decisions from NICE for Decadron in United Kingdom.
NICE TA1149 — — Decision pending classification
- Indication assessed: previously treated multiple myeloma
NICE has made a decision about Decadron for the treatment of previously treated multiple myeloma. Unfortunately, the details of the decision are not publicly available. The decision date and the cost-effectiveness assessment (ICER) are also not reported.
NICE TA1133 — — Decision pending classification
- Indication assessed: previously treated multiple myeloma
NICE recommended Decadron for the treatment of previously treated multiple myeloma. This decision was made with the support of a Patient Access Scheme and a commercial arrangement. No restrictions were placed on the use of Decadron.
NICE TA974 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Decadron for the treatment of previously treated multiple myeloma. This decision was made based on a patient access scheme and commercial arrangement. No restrictions were placed on the use of Decadron.
NICE TA970 — ✓ Recommended
- Indication assessed: treating relapsed and refractory multiple myeloma after 4 or more treatments
NICE recommended Decadron for treating relapsed and refractory multiple myeloma after 4 or more treatments. This decision was made without a reported ICER. A commercial arrangement was in place for this recommendation.
NICE TA968 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
NICE TA917 — ✓ Recommended
- Indication assessed: untreated multiple myeloma when a stem cell transplant is unsuitable
NICE recommended Decadron for the treatment of untreated multiple myeloma when a stem cell transplant is unsuitable. This decision was made based on a commercial arrangement. No restriction or condition was placed on the use of Decadron for this indication.
NICE TA897 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Decadron for the treatment of previously treated multiple myeloma. This decision was made based on a patient access scheme and commercial arrangement. No restrictions were placed on the use of Decadron.
NICE TA870 — ✓ Recommended
- Indication assessed: treating relapsed or refractory multiple myeloma
NICE recommended Decadron for treating relapsed or refractory multiple myeloma. This decision was made based on a patient access scheme and commercial arrangement. No restrictions were placed on the use of Decadron for this indication.
NICE TA841 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
NICE TA824 — ✓ Recommended
- Indication assessed: treating diabetic macular oedema
NICE recommended Decadron for treating diabetic macular oedema. This decision was made without a reported cost-effectiveness analysis. There are no restrictions or conditions associated with this recommendation.
NICE TA726 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not be making a recommendation on the use of Decadron for this indication. The decision to terminate was made without a recommendation on cost-effectiveness or a patient access scheme.
NICE TA727 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
NICE TA695 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Decadron for the treatment of previously treated multiple myeloma. This decision was made based on a Patient Access Scheme and a commercial arrangement. No restrictions were placed on the use of Decadron.
NICE TA658 — ✓ Recommended (Cancer Drugs Fund)
- Indication assessed: treating relapsed and refractory multiple myeloma
NICE recommended Decadron for treating relapsed and refractory multiple myeloma. This decision was made based on a commercial arrangement, which suggests that the drug's price was negotiated with the manufacturer. No restrictions were placed on the use of Decadron for this indication.
NICE TA634 — — Appraisal terminated
- Indication assessed: untreated multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for the treatment of untreated multiple myeloma. This decision means that NICE will not be making a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
NICE TA602 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
NICE TA229 — ✓ Recommended
- Indication assessed: the treatment of macular oedema secondary to retinal vein occlusion
NICE recommended Decadron for the treatment of macular oedema secondary to retinal vein occlusion. This decision was made without any restrictions or conditions. The cost basis of this decision is not reported.
NICE TA603 — — Appraisal terminated
- Indication assessed: untreated multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for the treatment of untreated multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The decision to terminate was made without a recommendation on the cost-effectiveness of Decadron, as the ICER was not reported.
NICE TA586 — ✓ Recommended
- Indication assessed: multiple myeloma after 1 treatment with bortezomib
NICE recommended Decadron for the treatment of multiple myeloma in adults who have had one treatment with bortezomib. This decision was made based on a commercial arrangement. No restriction or condition was placed on the use of Decadron.
NICE TA587 — ✓ Recommended
- Indication assessed: previously untreated multiple myeloma
NICE recommended Decadron for the treatment of previously untreated multiple myeloma. This decision was made based on a commercial arrangement, indicating a negotiated price with the manufacturer. No restrictions or conditions were placed on the use of Decadron for this indication.
NICE TA460 — ✓ Recommended
- Indication assessed: treating non-infectious uveitis
NICE recommended Decadron for treating non-infectious uveitis. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Decadron for this indication.
NICE TA454 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Decadron for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Decadron for this indication. The cost-effectiveness of Decadron was not reported as part of this decision.
Decadron in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Decadron approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Decadron in United Kingdom?
Generic (originally Merck) is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Decadron been assessed by UK health technology agencies?
Yes — 22 UK HTA decisions on record from NICE.